Skip to main content
Yingju Xu on Muck Rack

Yingju Xu

As seen in: ACS Publications
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingju

Contact Yingju, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Scalable Synthesis of a Dual TLR7/8 Agonist via Highly Selective N2-Alkylation of 1H-Pyrazolo[4,3-d]pyrimidine

|
By Kai-Jiong Xiao, Yingju Xu, LU CHEN, Zheng Wu
| dx.doi.org
Open in Who Shared Issue with article?

Process Development toward a Key Fragment of the PCSK9 Inhibitor Enlicitide Decanoate

|
By Kai-Jiong Xiao, Yonggang Chen, Yingju Xu, Gao Shang
| ACS Publications
Open in Who Shared Issue with article?

Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19

|
By Patrick S. Fier, Yingju Xu, Marc R. Poirier, Gilmar A. Brito
| ACS Publications
Note Made available for a limited time for personal research and study only License. Molnupiravir (MK-4482, formerly EIDD-2801; Figure 1A) (1) is an orally dosed unnatural nucleoside prodrug that has demonstrated antiviral activity in preclinical studies (2−4) and was recently shown to significantly reduce the rate of hospitalization and death in patients diagnosed with COVID-19.
Open in Who Shared Issue with article?
See all 5 articles